Skinvisible Competitors

Skinvisible (OTCMKTS:SKVI) and Inspyr Therapeutics (OTCMKTS:NSPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Skinvisible and Inspyr Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Skinvisible and Inspyr Therapeutics' revenue, earnings per share and valuation.

Inspyr Therapeutics has lower revenue, but higher earnings than Skinvisible.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Skinvisible and Inspyr Therapeutics, as provided by MarketBeat.com.

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500. Comparatively, Inspyr Therapeutics has a beta of -16.55, meaning that its stock price is 1,755% less volatile than the S&P 500.

Summary

Inspyr Therapeutics beats Skinvisible on 3 of the 5 factors compared between the two stocks.

Skinvisible (OTCMKTS:SKVI) and Boston Therapeutics (OTCMKTS:BTHE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, valuation, profitability, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Skinvisible and Boston Therapeutics, as provided by MarketBeat.com.

Profitability

This table compares Skinvisible and Boston Therapeutics' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Skinvisible and Boston Therapeutics' revenue, earnings per share and valuation.

Skinvisible has higher revenue and earnings than Boston Therapeutics.

Volatility & Risk

Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500. Comparatively, Boston Therapeutics has a beta of -0.16, meaning that its stock price is 116% less volatile than the S&P 500.

Summary

Skinvisible beats Boston Therapeutics on 4 of the 6 factors compared between the two stocks.

VIVUS (OTCMKTS:VVUSQ) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares VIVUS and Skinvisible's net margins, return on equity and return on assets.

Institutional and Insider Ownership

7.3% of VIVUS shares are held by institutional investors. 12.0% of VIVUS shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares VIVUS and Skinvisible's revenue, earnings per share and valuation.

Skinvisible has lower revenue, but higher earnings than VIVUS.

Analyst Ratings

This is a summary of recent ratings and recommmendations for VIVUS and Skinvisible, as provided by MarketBeat.

Risk and Volatility

VIVUS has a beta of -3.25, meaning that its stock price is 425% less volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, meaning that its stock price is 144% less volatile than the S&P 500.

Skinvisible (OTCMKTS:SKVI) and ImmunoCellular Therapeutics (OTCMKTS:IMUCD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Skinvisible and ImmunoCellular Therapeutics, as reported by MarketBeat.

Profitability

This table compares Skinvisible and ImmunoCellular Therapeutics' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Skinvisible and ImmunoCellular Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Skinvisible has higher revenue and earnings than ImmunoCellular Therapeutics.

Volatility & Risk

Skinvisible has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500. Comparatively, ImmunoCellular Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Summary

ImmunoCellular Therapeutics beats Skinvisible on 3 of the 5 factors compared between the two stocks.

Capstone Therapeutics (OTCMKTS:CAPS) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

Risk & Volatility

Capstone Therapeutics has a beta of 176.15, suggesting that its share price is 17,515% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, suggesting that its share price is 144% less volatile than the S&P 500.

Valuation & Earnings

This table compares Capstone Therapeutics and Skinvisible's gross revenue, earnings per share (EPS) and valuation.

Capstone Therapeutics has higher revenue and earnings than Skinvisible.

Institutional and Insider Ownership

2.6% of Capstone Therapeutics shares are held by institutional investors. 42.8% of Capstone Therapeutics shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Capstone Therapeutics and Skinvisible's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Capstone Therapeutics and Skinvisible, as reported by MarketBeat.

Summary

Capstone Therapeutics beats Skinvisible on 6 of the 8 factors compared between the two stocks.

W World (OTCMKTS:WWHC) and Skinvisible (OTCMKTS:SKVI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, valuation and profitability.

Volatility & Risk

W World has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500. Comparatively, Skinvisible has a beta of -0.44, suggesting that its stock price is 144% less volatile than the S&P 500.

Earnings and Valuation

This table compares W World and Skinvisible's gross revenue, earnings per share (EPS) and valuation.

W World has higher earnings, but lower revenue than Skinvisible.

Profitability

This table compares W World and Skinvisible's net margins, return on equity and return on assets.

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 61.1% of W World shares are held by insiders. Comparatively, 53.0% of Skinvisible shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for W World and Skinvisible, as provided by MarketBeat.com.

Summary

W World beats Skinvisible on 5 of the 6 factors compared between the two stocks.